Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Phenomenex Chiral Screening Services Now Offered in China

Published: Wednesday, December 05, 2012
Last Updated: Wednesday, December 05, 2012
Bookmark and Share
Collaboration with Chinese Academy of Sciences ensures fast, high-quality screening.

Phenomenex Inc. has announced the extension of its Chiral Screening Service to pharmaceutical and natural products customers in China.

The service is offered in collaboration with the Chinese Academy of Sciences (CAS), a leading academic and R&D center under which the Shanghai Institute of Organic Chemistry (SIOC) has developed a strong chiral team that works closely with Phenomenex.

The free Chiral Screening Service provides target screening using a library of HPLC columns including the Phenomenex Lux™ polysaccharide-based offerings, which demonstrate a success rate approaching 90 percent.

After resolving the chiral compound, Phenomenex delivers a method development and optimization plan to the customer within 10 business days - the same rapid turnaround the service promises in the U.S. and Europe.

“Our customer base in China has been growing rapidly and the expansion of our services will help us better serve them,” explains Michael Klein, brand manager for Phenomenex. “By teaming up with the CAS-SIOC, we are able to quickly roll out our rapid-response service.”

Enantiomers of chiral compounds may have different pharmacological effects in biological systems and they must be identified and evaluated separately.

“Resolving chiral compounds is relatively difficult, and column selection can be complicated,” continues Klein. “Our Chiral Screening Service eliminates time-consuming guesswork and also gives customers a chance to ‘test-drive’ our Lux columns.”

The Phenomenex team of chiral experts will customize a plan for each screening project, taking into account specific requirements and overall separation goals.

Once a project is completed, the customer will receive a report that details the optimal method including information on the chiral stationary phase (CSP) selected for the separation, running conditions and associated chromatograms.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Phenomenex Launches Innovative, Industry-Focused Websites
Company builds on award-winning web presence with new digital experience.
Friday, February 22, 2013
Scientific News
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!